Danaher (NYSE:DHR) Rating Increased to Buy at Wall Street Zen

Danaher (NYSE:DHR - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Sunday.

• 3 Stocks Offering Strong Value and Stability

DHR has been the subject of several other reports. UBS Group reduced their target price on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 22nd. JPMorgan Chase & Co. reduced their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. Finally, Jefferies Financial Group reduced their target price on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $263.24.

Get Our Latest Stock Analysis on Danaher

Danaher Stock Down 0.5%

• Agilent Technologies Thrives From the Forever Chemicals Crackdown

DHR opened at $189.54 on Friday. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $135.65 billion, a price-to-earnings ratio of 35.90, a P/E/G ratio of 2.66 and a beta of 0.80. The business has a 50 day moving average of $192.72 and a 200-day moving average of $213.59.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, sell-side analysts anticipate that Danaher will post 7.63 earnings per share for the current year.

Insider Activity

• Will Danaher stock hit new highs in 2024?

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Danaher

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its position in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Geode Capital Management LLC increased its position in Danaher by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after purchasing an additional 315,446 shares during the period. Norges Bank acquired a new stake in Danaher in the fourth quarter worth about $2,130,740,000. Finally, Bank of New York Mellon Corp increased its position in Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

• Five stocks we like better than Danaher
• Manufacturing Stocks Investing
• Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
• Russell 2000 Index, How Investors Use it For Profitable Trading
• 3 Overlooked Dividend Plays for Income in Volatile Times
• 3 Defense Stocks Set to Benefit From Increased Military Spending
• AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here